Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HxB2.WT.Core-C4b
- Development stage
- Phase 1
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
HxB2.WT.Core-C4b is an experimental HIV vaccine immunogen designed to boost and further mature broadly neutralizing antibody (bnAb)-precursor B-cell lineages elicited by a priming immunogen (426c.Mod.Core-C4b). It is derived from the HxB2 HIV Env protein and targets the CD4-binding site of HIV envelope. In current clinical trials, it is adjuvanted with 3M-052 AF + Alum and used as a booster following priming with 426c.Mod.Core-C4b.
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on HxB2.WT.Core-C4b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HxB2.WT.Core-C4b.